natgillin/translations-raw huggingface dataset:
Docetaxel Mylan 20 mg/1 ml sterile concentrate docetaxel
Docetaxel Mylan 20 mg/1 ml koncentrat za raztopino za infundiranje docetaksel
Docetaxel Mylan 200 mg/10 ml concentrate for solution for infusion
Docetaxel Mylan 200 mg/10 ml koncentrat za raztopino za infundiranje
Docetaxel Mylan 200 mg/10 ml concentrate for solution for infusion docetaxel
Docetaxel Mylan 200 mg/10 ml koncentrat za raztopino za infundiranje docetaksel
Docetaxel Mylan 200 mg/10 ml sterile concentrate docetaxel
Docetaxel Mylan 200 mg/10 ml koncentrat za raztopino za infundiranje docetaksel
Docetaxel Mylan 80 mg/4 ml concentrate for solution for infusion
Docetaxel Mylan 80 mg/4 ml koncentrat za raztopino za infundiranje
Docetaxel Mylan 80 mg/4 ml concentrate for solution for infusion docetaxel
Docetaxel Mylan 80 mg/4 ml koncentrat za raztopino za infundiranje docetaksel
Docetaxel Mylan 80 mg/4 ml sterile concentrate docetaxel
Docetaxel Mylan 80 mg/4 ml koncentrat za raztopino za infundiranje docetaksel
Docetaxel Mylan docetaxel
Docetaxel Mylan docetaksel
Docetaxel Mylan has been prescribed by your doctor for the treatment of breast cancer, special forms of lung cancer (non-small cell lung cancer), prostate cancer, gastric cancer or head and neck cancer:
Zdravnik vam je zdravilo Docetaxel Mylan predpisal za zdravljenje raka dojke, posebne vrste pljučnega raka (nedrobnocelični pljučni rak), raka prostate, raka želodca ali raka glave in vratu:
Docetaxel Mylan is a ‘generic medicine’.
Docetaxel Mylan je „generično zdravilo“.
Docetaxel Mylan is indicated for the treatment of patients with locally advanced or metastatic non- small cell lung cancer after failure of prior chemotherapy.
Zdravilo Docetaxel Mylan je indiciran za zdravljenje bolnikov z lokalno napredovalim ali metastatskim nedrobnoceličnim pljučnim rakom, pri katerih predhodna kemoterapija ni bila uspešna.
Docetaxel Mylan is only used when the neutrophil count (the level of a type of white blood cell in the blood) is normal (at least 1,500 cells/mm3).
Docetaxel Mylan se uporablja le, kadar je število nevtrofilcev (raven vrste belih krvnih celic v krvi) normalno (vsaj 1 500 celic/mm3).
Docetaxel Mylan is used with cisplatin and 5-fluorouracil (other anticancer medicines); head and neck cancer in patients whose cancer is advanced (has started to spread).
Zdravilo Docetaxel Mylan se uporablja sočasno s cisplatinom in 5–fluoroacilom (drugima zdraviloma proti raku); raka glave in vratu pri bolnikih z napredovalim rakom (ki se je začel širiti).
Docetaxel pharmacokinetics in the presence of prednisone was studied in patients with mestatic prostate cancer.
Farmakokinetiko docetaksela v prisotnosti prednizona so proučevali pri bolnikih z metastatskim rakom prostate.
Docetaxel plus trastuzumab was efficacious in patients whether or not they had received prior adjuvant anthracyclines.
Kombinacija docetaksela in trastuzumaba je bila pri bolnicah učinkovita ne glede na to, ali so prej dobile adjuvantne antracikline ali ne.
Docetaxel should be administered when the neutrophil count is ≥ 1,500 cells/mm3.
Docetaksel je treba aplicirati, ko je število nevtrofilcev ≥ 1.500 celic/mm .
Docetaxel should be administered when the neutrophil count is ≥1,500 cells/mm3.
Docetaksel je treba aplicirati, ko je število nevtrofilcev ≥ 1.500 celic/mm3.
Docetaxel should be administered with caution in patients concomitantly receiving potent CYP3A4 inhibitors (e.g. protease inhibitors like ritonavir, azole antifungals like ketoconazole or itraconazole).
Docetaksel se mora uporabljati pazljivo pri pacientih, ki sočasno jemljejo močne zaviralce CYP3A4 (npr. zaviralce proteaze kot je ritonavir, antimikotike, derivate azola kot sta ketokonazol ali itrakonazol).
Docetaxel TEVA
Docetaksel Teva
Docetaxel Teva 20 mg/0.72 ml concentrate and solvent for solution for infusion
Docetaksel Teva 20 mg/0,72 ml koncentrat in vehikel za raztopino za infundiranje
Docetaxel Teva 20 mg/0.72 ml concentrate and solvent for solution for infusion docetaxel
Docetaksel Teva 20 mg/0,72 ml koncentrat in vehikel za raztopino za infundiranje docetaksel
Docetaxel Teva 20 mg/0.72 ml concentrate for solution for infusion docetaxel
Docetaksel Teva 20 mg/0,72 ml koncentrat za raztopino za infundiranje docetaksel
Docetaxel Teva 20 mg/0.72 ml concentrate for solution for infusion is a clear viscous, yellow to brown-yellow solution containing 27.73 mg/ml docetaxel (anhydrous) in polysorbate 80.
Docetaksel Teva 20 mg/0,72 ml koncentrat za raztopino za infundiranje je bistra, viskozna, rumena do rjavorumena raztopina, ki vsebuje 27,73 mg brezvodnega docetaksela/ml v polisorbatu 80.
Docetaxel Teva 80 mg/2.88 ml concentrate and solvent for solution for infusion
Docetaksel Teva 80 mg/2,88 ml koncentrat in vehikel za raztopino za infundiranje
Docetaxel Teva 80 mg/2.88 ml concentrate for solution for infusion docetaxel
Docetaksel Teva 80 mg/2,88 ml koncentrat za raztopino za infundiranje docetaksel
Docetaxel Teva 80 mg/2.88 ml concentrate for solution for infusion is a clear viscous, yellow to brown-yellow solution containing 27.73 mg/ml docetaxel (anhydrous) in polysorbate 80.
Docetaksel Teva 80 mg/2,88 ml koncentrat za raztopino za infundiranje je bistra, viskozna, rumena do rjavorumena raztopina, ki vsebuje 27,73 mg brezvodnega docetaksela/ml v polisorbatu 80.
Docetaxel Teva 80 mg/2.88 ml vial
Zdravilo Docetaksel Teva 80 mg/2,88 ml viala
Docetaxel Teva in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer, in patients who have not previously received chemotherapy for this condition.
Zdravilo Docetaksel Teva v kombinaciji s cisplatinom je indicirano za zdravljenje neresektabilnega, lokalno napredovalega ali metastatskega nedrobnoceličnega pljučnega raka pri bolnikih, ki zaradi te bolezni še niso dobivali kemoterapije.
Docetaxel Teva in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.
Zdravilo Docetaksel Teva v kombinaciji s trastuzumabom je indicirano za zdravljenje bolnic z metastatskim rakom dojke, katerih tumorji imajo prekomerno izražen HER2 in ki se predhodno niso zdravile s kemoterapijo za metastatsko bolezen.
Docetaxel Teva is a ‘generic medicine’.
Zdravilo Docetaxel Teva je „generično zdravilo“.
Docetaxel Teva is an antineoplastic agent and, as with other potentially toxic compounds, caution should be exercised when handling it and preparing Docetaxel solutions.
Zdravilo Docetaksel Teva je antineoplastično zdravilo in tako kot pri ravnanju z drugimi potencialno toksičnimi spojinami je tudi med ravnanjem in pripravo raztopin docetaksela potrebna previdnost.
Docetaxel Teva is an antineoplastic agent and, as with other potentially toxic compounds, caution should be exercised when handling it and preparing Docetaxel Teva solutions.
Docetaksel Teva je antineoplastično zdravilo in tako kot pri ravnanju z drugimi potencialno toksičnimi spojinami je tudi med ravnanjem in pripravo raztopin zdravila Docetaksel Teva potrebna previdnost.
Docetaxel Teva is indicated for the treatment of patients with locally advanced or metastatic non- small cell lung cancer after failure of prior chemotherapy.
Zdravilo Docetaksel Teva je indicirano za zdravljenje bolnikov z lokalno napredovalim ali metastatskim nedrobnoceličnim pljučnim rakom, pri katerih predhodna kemoterapija ni bila uspešna.
Docetaxel Teva is used with cisplatin and 5-fluorouracil (other anticancer medicines); head and neck cancer in patients whose cancer is locally advanced (a cancer that has grown but has not spread).
Zdravilo Docetaxel Teva se uporablja s cisplatinom in 5-fluoroacilom (drugima zdraviloma proti raku); lokalno napredovalem raku glave in vratu pri bolnikih (rak je zrastel, vendar se ni razširil).
Docetaxel Teva monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy.
Zdravilo Docetaksel Teva v monoterapiji je indicirano za zdravljenje bolnic z lokalno napredovalim ali metastatskim rakom dojke, pri katerih predhodna citotoksična terapija ni bila uspešna.
Docetaxel Teva must NOT be administered if you are pregnant unless clearly indicated by your doctor.
Zdravila Docetaksel Teva NE smete dobiti, razen če je to nujno potrebno.
Docetaxel Teva Pharma 20 mg concentrate and solvent for solution for infusion
Docetaxel Teva Pharma 20 mg koncentrat in vehikel za raztopino za infundiranje
Docetaxel Teva Pharma 20 mg concentrate and solvent for solution for infusion docetaxel
Docetaxel Teva Pharma 20 mg koncentrat in vehikel za raztopino za infundiranje docetaksel
Docetaxel Teva Pharma 20 mg concentrate for solution for infusion docetaxel
Docetaxel Teva Pharma 20 mg koncentrat za raztopino za infundiranje docetaksel
Docetaxel Teva Pharma 80 mg concentrate and solvent for solution for infusion
Docetaxel Teva Pharma 80 mg koncentrat in vehikel za raztopino za infundiranje
Docetaxel Teva Pharma 80 mg concentrate and solvent for solution for infusion docetaxel
Docetaxel Teva Pharma 80 mg koncentrat in vehikel za raztopino za infundiranje docetaksel
Docetaxel Teva Pharma 80 mg concentrate for solution for infusion docetaxel
Docetaxel Teva Pharma 80 mg koncentrat za raztopino za infundiranje docetaksel
Docetaxel Teva Pharma 80 mg vial
Zdravilo Docetaxel Teva Pharma 80 mg viala
Docetaxel Teva Pharma concentrate for solution for infusion is a clear viscous, yellow to brown- yellow solution.
Zdravilo Docetaxel Teva Pharma koncentrat za raztopino za infundiranje je bistra, viskozna, rumena do rjavorumena raztopina.
Docetaxel Teva Pharma docetaxel
Docetaxel Teva Pharma
Docetaxel Teva Pharma is a ‘generic medicine’.
Zdravilo Docetaxel Teva Pharma je „generično zdravilo“.
Docetaxel Teva Pharma is an antineoplastic agent and, as with other potentially toxic compounds, caution should be exercised when handling it and preparing Docetaxel Teva Pharma solutions.
Zdravilo Docetaxel Teva Pharma je antineoplastično zdravilo in tako kot pri ravnanju z drugimi potencialno toksičnimi spojinami je tudi med ravnanjem in pripravo raztopin zdravila Docetaxel Teva Pharma potrebna previdnost.
Docetaxel Teva Pharma is only used when the neutrophil count (the level of a type of white blood cell in the blood) is normal (at least 1,500 cells/mm3).
Docetaxel Teva Pharma se uporablja le, kadar je število nevtrofilcev (raven vrste belih krvnih celic v krvi) običajno (vsaj 1 500 celic/mm3).
Docetaxel Teva Pharma is supplied as single-dose vials.
Docetaxel Teva Pharma je na voljo v vialah z enim odmerkom.
Docetaxel Teva Pharma is supplied as single-dose vials.
Zdravilo Docetaxel Teva Pharma je na voljo v vialah z enim odmerkom.
Docetaxel Teva Pharma is used on its own after other treatments have failed; non-small cell lung cancer.
Zdravilo Docetaxel Teva Pharma se lahko uporablja kot monoterapija po neuspešnih drugih oblikah zdravljenja; nedrobnoceličnega pljučnega raka.
Docetaxel Teva Pharma monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy.
Zdravilo Docetaxel Teva Pharma v monoterapiji je indicirano za zdravljenje bolnic z lokalno napredovalim ali metastatskim rakom dojke, pri katerih predhodna citotoksična terapija ni bila uspešna.
Docetaxel Teva Pharma must NOT be administered if you are pregnant unless clearly indicated by your doctor.
Zdravila Docetaxel Teva Pharma NE smete dobiti, razen če je to nujno potrebno.
Docetaxel was administered as a 1-hour infusion, all other medicinal products were given as intravenous bolus on day one.
Docetaksel so aplicirali v 1-urni infuziji, vsa ostala zdravila pa v intravenskem bolusu prvi dan.
Docetaxel was administered as a 1-hour infusion, all other medicinal products were given as intravenous bolus on day one.
Docetaksel so aplicirali v 1-urni infuziji, vse ostale medicinske produkte pa v intravenskem bolusu prvi dan.
Docetaxel was administered as a 1-hour infusion, all other medicinal products were given intraveinously on day 1 every three weeks.
Zdravilo Docetaksel Teva je bilo uporabljeno v 1-urni infuziji, vsa druga zdravila pa intravensko 1. dan na tri tedne.
Docetaxel was administered as a 1-hour infusion; all other medicinal products were given as intravenous bolus on day one.
Docetaksel so aplicirali v enourni infuziji, vsa ostala zdravila pa v intravenskem bolusu prvi dan.
Docetaxel was administered as follows:
Odmerjanje docetaksela je bilo naslednje:
Docetaxel was given as an initial dose of 75 mg/m2 as an intravenous infusion every three weeks for at least 6 cycles.
Docetaksel je bil dan v začetnem odmerku 75 mg/m2 v intravenski infuziji vsake 3 tedne vsaj 6 ciklusov.
Docetaxel was given as an initial dose of 75 mg/m2 IV infusion every three weeks with the option to escalate to 100 mg/m2 at the investigator’s discretion if the initial dose was well tolerated.
Docetaksel so dali v uvajalnem odmerku 75 mg/m2 v obliki intravenske infuzije vsake tri tedne z možnostjo povečanja na 100 mg/m2 glede na mnenje raziskovalca, če je bolnica uvajalni odmerek dobro prenesla.
Docetaxel Winthrop 160 mg/8 ml concentrate for solution for infusion docetaxel
Docetaxel Winthrop 160 mg/8 ml koncentrat za raztopino za infundiranje docetaksel
Docetaxel Winthrop 160 mg/8 ml concentrate for solution for infusion requires NO prior dilution with a solvent and is ready to add to the infusion solution.
Zdravilo Docetaxel Winthrop 160 mg/8 ml koncentrat za raztopino za infundiranje NE POTREBUJE predhodnega redčenja z vehiklom in je pripravljen za dodajanje raztopini za infundiranje.
Docetaxel Winthrop 160 mg/8 ml concentrate for solution for infusion.
Docetaxel Winthrop 160 mg/8 ml koncentrat za raztopino za infundiranje
Docetaxel Winthrop 20 mg/1 ml concentrate for solution for infusion
Docetaxel Winthrop 20 mg/1 ml koncentrat za raztopino za infundiranje
Docetaxel Winthrop 20 mg/1 ml concentrate for solution for infusion docetaxel
Docetaxel Winthrop 20 mg/1 ml koncentrat za raztopino za infundiranje docetaksel
Docetaxel Winthrop 20 mg/1 ml concentrate for solution for infusion requires NO prior dilution with a solvent and is ready to add to the infusion solution.
Zdravilo Docetaxel Winthrop 20 mg/1 ml koncentrat za raztopino za infundiranje NE POTREBUJE predhodnega redčenja z vehiklom in je pripravljen za dodajanje raztopini za infundiranje.
Docetaxel Winthrop 80 mg/4 ml concentrate for solution for infusion
Docetaxel Winthrop 80 mg/4 ml koncentrat za raztopino za infundiranje
Docetaxel Winthrop 80 mg/4 ml concentrate for solution for infusion docetaxel
Docetaxel Winthrop 80 mg/4 ml koncentrat za raztopino za infundiranje docetaksel
Docetaxel Winthrop 80 mg/4 ml concentrate for solution for infusion requires NO prior dilution with a solvent and is ready to add to the infusion solution.
Zdravilo Docetaxel Winthrop 80 mg/4 ml koncentrat za raztopino za infundiranje NE POTREBUJE predhodnega redčenja z vehiklom in je pripravljen za dodajanje raztopini za infundiranje.
Docetaxel Winthrop as single agent
Zdravilo Docetaxel Winthrop v monoterapiji
Docetaxel Winthrop can be used on its own after other treatments have failed.
Zdravilo Docetaxel Winthrop se lahko uporablja samostojno po neuspešnih drugih oblikah zdravljenja.
Docetaxel Winthrop concentrate for solution for infusion is a pale yellow to brownish-yellow solution.
Zdravilo Docetaxel Winthrop koncentrat za raztopino za infundiranje je bledorumena do rjavkastorumena raztopina.
Docetaxel Winthrop contains alcohol.
Zdravilo Docetaxel Winthrop vsebuje alkohol.
Docetaxel Winthrop contains ethanol (alcohol)
Zdravilo Docetaxel Winthrop vsebuje etanol (alkohol).
Docetaxel Winthrop docetaxel
Docetaxel Winthrop docetaksel
Docetaxel Winthrop has been prescribed by your doctor for the treatment of breast cancer, special forms of lung cancer (non-small cell lung cancer), prostate cancer, gastric cancer or head and neck cancer:
Zdravnik vam je zdravilo Docetaxel Winthrop predpisal za zdravljenje raka dojke, posebne vrste pljučnega raka (nedrobnocelični pljučni rak), raka prostate, raka želodca ali raka glave in vratu:
Docetaxel Winthrop has been studied in over 4,000 breast-cancer patients, around 2,000 non-small- cell-lung-cancer patients, 1,006 prostate-cancer patients, 457 gastric-adenocarcinoma patients and 897 head- and neck-cancer patients.
Zdravilo Docetaxel Winthrop so proučevali pri več kot 4 000 bolnicah z rakom dojke, približno 2 000 bolnikih z nedrobnoceličnim pljučnim rakom, 1 006 bolnikih z rakom prostate, 457 bolnikih z želodčnim adenokarcinomom in 897 bolnikih z rakom glave in vratu.
Docetaxel Winthrop in combination with capecitabine
Zdravilo Docetaxel Winthrop v kombinaciji s kapecitabinom
Docetaxel Winthrop in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy.
Zdravilo Docetaxel Winthrop v kombinaciji s kapecitabinom je indiciran za zdravljenje bolnic z lokalno napredovalim ali metastatskim rakom dojke po neuspehu citotoksične kemoterapije.
Docetaxel Winthrop in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.
Zdravilo Docetaxel Winthrop je v kombinaciji s cisplatinom in 5-fluorouracilom indiciran za indukcijsko zdravljenje bolnikov z lokalno napredovalim skvamoznoceličnim karcinomom glave in vratu.
Docetaxel Winthrop in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.
Zdravilo Docetaxel Winthrop je v kombinaciji s cisplatinom in 5-fluorouracilom indiciran za zdravljenje bolnikov z metastatskim adenokarcinomom želodca, vključno z adenokarcinomom na gastroezofagealnem prehodu, ki predhodno še niso bili zdravljeni s kemoterapijo za metastatsko bolezen.
Docetaxel Winthrop in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer, in patients who have not previously received chemotherapy for this condition.
Zdravilo Docetaxel Winthrop v kombinaciji s cisplatinom je indiciran za zdravljenje neresektabilnega, lokalno napredovalega ali metastatskega nedrobnoceličnega pljučnega raka pri bolnikih, ki zaradi te bolezni še niso dobivali kemoterapije.
Docetaxel Winthrop in combination with doxorubicin
Zdravilo Docetaxel Winthrop v kombinaciji z doksorubicinom
Docetaxel Winthrop in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:
Zdravilo Docetaxel Winthrop je v kombinaciji z doksorubicinom in ciklofosfamidom indiciran za adjuvantno zdravljenje bolnic z:
Docetaxel Winthrop in combination with doxorubicin and cyclophosphamide: adjuvant therapy
Zdravilo Docetaxel Winthrop v kombinaciji z doksorubicinom in ciklofosfamidom: adjuvantno zdravljenje
Docetaxel Winthrop in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.
Zdravilo Docetaxel Winthrop v kombinaciji z doksorubicinom je indiciran za zdravljenje bolnic z lokalno napredovalim ali metastatskim rakom dojke, ki zaradi te bolezni še niso prejemale citotoksične terapije.
Docetaxel Winthrop in combination with platinum agents in chemotherapy-naïve patients
Docetaksel v kombinaciji s platinskimi zdravili pri bolnikih, ki še niso bili zdravljeni s kemoterapijo
Docetaxel Winthrop in combination with platinum agents in chemotherapy-naïve patients
Zdravilo Docetaxel Winthrop v kombinaciji s platinskimi zdravili pri bolnikih, ki še niso bili zdravljeni s kemoterapijo
Docetaxel Winthrop in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.
Zdravilo Docetaxel Winthrop je v kombinaciji s prednizonom ali prednizolonom indiciran za zdravljenje bolnikov z metastatskim hormonsko neodzivnim rakom prostate.
Docetaxel Winthrop in combination with trastuzumab
Zdravilo Docetaxel Winthrop v kombinaciji s trastuzumabom
Docetaxel Winthrop in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours over express HER2 and who previously have not received chemotherapy for metastatic disease.
Zdravilo Docetaxel Winthrop je indiciran v kombinaciji s trastuzumabom za zdravljenje bolnic z metastatskim rakom dojke, katerih tumorji imajo čezmerno izražen HER2 in ki predhodno niso bile zdravljene s kemoterapijo za metastatsko bolezen.
Docetaxel Winthrop is a medicine that contains the active substance docetaxel.
Docetaxel Winthrop je zdravilo, ki vsebuje zdravilno učinkovino docetaksel.
Docetaxel Winthrop is an antineoplastic agent and, as with other potentially toxic compounds, caution should be exercised when handling it and preparing Docetaxel Winthrop solutions.
Docetaxel Winthrop je antineoplastično zdravilo in tako kot pri ravnanju z drugimi potencialno toksičnimi spojinami je tudi med rokovanjem in pripravo raztopin zdravila Docetaxel Winthrop potrebna previdnost.
Docetaxel Winthrop is given as a one-hour infusion every three weeks.
Zdravilo Docetaxel Winthrop se daje v obliki enourne infuzije vsake tri tedne.
Docetaxel Winthrop is indicated for the treatment of patients with locally advanced or metastatic non- small cell lung cancer after failure of prior chemotherapy.
Zdravilo Docetaxel Winthrop je indiciran za zdravljenje bolnikov z lokalno napredovalim ali metastatskim nedrobnoceličnim pljučnim rakom, pri katerih predhodna kemoterapija ni bila uspešna.
Docetaxel Winthrop is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy.
Zdravilo Docetaxel Winthrop je indiciran za zdravljenje bolnikov z lokalno napredovalim ali metastatskim nedrobnoceličnim pljučnim rakom, pri katerih predhodna kemoterapija ni bila uspešna.
Docetaxel Winthrop is only used when the neutrophil count (the level of a type of white blood cell in the blood) is normal (at least 1,500 cells/mm3).
Zdravilo Docetaxel Winthrop se uporablja le, kadar je število nevtrofilcev (raven vrste belih krvnih celic v krvi) normalno (vsaj 1 500 celic/mm3).
Docetaxel Winthrop is used to treat the following types of cancer:
Zdravilo Docetaxel Winthrop se uporablja za zdravljenje naslednjih vrst raka:
Docetaxel Winthrop is used with cisplatin and 5-fluorouracil (other anticancer medicines); head and neck cancer in patients whose cancer is locally advanced (a cancer that has grown but has not spread).
Zdravilo Docetaxel Winthrop se uporablja s cisplatinom in 5–fluoroacilom (drugima zdraviloma proti raku); lokalno napredovalem raku glave in vratu pri bolnikih (rak je zrastel, vendar se ni razširil).
Docetaxel Winthrop is used with cisplatin and 5-fluorouracil.
Zdravilo Docetaxel Winthrop se uporablja s cisplatinom in 5-fluoroacilom.
Docetaxel Winthrop is used with prednisone or prednisolone (anti-inflammatory medicines);
Zdravilo Docetaxel Winthrop se uporablja s prednizonom ali prednizolonom (protivnetnima zdraviloma);
Docetaxel Winthrop monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy.
Zdravilo Docetaxel Winthrop v monoterapiji je indiciran za zdravljenje bolnic z lokalno napredovalim ali metastatskim rakom dojke, pri katerih predhodna citotoksična terapija ni bila uspešna.
Docetaxel Winthrop must NOT be administered if you are pregnant unless clearly indicated by your doctor.
Zdravila Docetaxel Winthrop NE smete dobiti, če ste noseči, razen če vam vaš zdravnik ne odredi drugače.
Docetaxel Winthrop must not be used in patients who have a neutrophil count of less than 1,500 cells/mm3 or who have severe problems with their liver.
Zdravilo Docetaxel Winthrop se ne sme uporabljati pri bolnikih, pri katerih je število nevtrofilcev manjše od 1 500 celic/mm3, ali pri bolnikih s hudimi težavami z jetri.